Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Sezer A, Kilickap S, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, Turk HM, Cicin I, Bentsion D, Gladkov O, Clingan P, Sriuranpong V, Rizvi N, Gao B, Li S, Lee S, McGuire K, Chen CI, Makharadze T, Paydas S, Nechaeva M, Seebach F, Weinreich DM, Yancopoulos GD, Gullo G, Lowy I, Rietschel P. Sezer A, et al. Lancet. 2021 Feb 13;397(10274):592-604. doi: 10.1016/S0140-6736(21)00228-2. Lancet. 2021. PMID: 33581821 Clinical Trial.
Patients with distal intestinal gastric cancer have superior outcome with addition of taxanes to combination chemotherapy, while proximal intestinal and diffuse gastric cancers do not: does biology and location predict chemotherapy benefit?
Sedef AM, Köse F, Sümbül AT, Doğan Ö, Beşen AA, Tatlı AM, Mertsoylu H, Sezer A, Muallaoğlu S, Özyılkan Ö, Abalı H. Sedef AM, et al. Among authors: sezer a. Med Oncol. 2015 Feb;32(2):476. doi: 10.1007/s12032-014-0476-8. Epub 2015 Jan 9. Med Oncol. 2015. PMID: 25572818
Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.
Mertsoylu H, Köse F, Sümbül AT, Sedef AM, Doğan Ö, Besen AA, Parlak C, Fındıkçıoğlu A, Muallaoğlu S, Sezer A, Sakallı H, Özyılkan Ö. Mertsoylu H, et al. Among authors: sezer a. Med Sci Monit. 2015 Mar 3;21:661-6. doi: 10.12659/MSM.892730. Med Sci Monit. 2015. PMID: 25731741 Free PMC article.
Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study.
Urun Y, Yasar HA, Turna H, Esin E, Sedef AM, Alkan A, Oksuzoglu B, Ozdemir N, Sendur MN, Sezer A, Kılıckap S, Utkan G, Akman T, Akbulut H, Celik I, Abalı H. Urun Y, et al. Among authors: sezer a. J Oncol Pharm Pract. 2019 Oct;25(7):1658-1664. doi: 10.1177/1078155218805539. Epub 2018 Nov 6. J Oncol Pharm Pract. 2019. PMID: 30400750
Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study.
Arzu Yaşar H, Turna H, Esin E, Murat Sedef A, Alkan A, Oksuzoglu B, Ozdemir N, Sendur MN, Sezer A, Kılıckap S, Utkan G, Akbulut H, Celik I, Abalı H, Urun Y. Arzu Yaşar H, et al. Among authors: sezer a. J Oncol Pharm Pract. 2020 Mar;26(2):267-272. doi: 10.1177/1078155219840796. Epub 2019 Mar 29. J Oncol Pharm Pract. 2020. PMID: 30924738
Re: Combination of radiotherapy and immunotherapy? Do timing and dose matter?
Ürün Y, Yaşar HA, Turna H, Kılıçkap S, Sezer A, Öksüzoğlu B, Özdemir N, Şendur MN, Abalı H. Ürün Y, et al. Among authors: sezer a. J Oncol Pharm Pract. 2019 Dec;25(8):2062-2063. doi: 10.1177/1078155219858176. Epub 2019 Jun 21. J Oncol Pharm Pract. 2019. PMID: 31226917 No abstract available.
GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients.
Peled N, Gillis R, Kilickap S, Froesch P, Orlov S, Filippova E, Demirci U, Christopoulos P, Cicin I, Basal FB, Yilmaz C, Fedor M, Korkmaz T, Paydas S, Gautschi O, Zirtiloglu A, Eralp Y, Cinkir HY, Sezer A, Erman M, Tural D, Turna H, Mazieres J, Dudnik E, Reguart N, Camidge DR, Ng TL, Şenler FÇ, Beypınar İ, Yazılıtaş D, Demirkazık A, Karaoğlu A, Okutur K, Coşkun HŞ, Şendur MAN, Isikdogan A, Cabuk D, Yumuk PF, Yıldız I, Kaplan MA, Özyılkan Ö, Öztop İ, Olmez OF, Aydin K, Aydıner A, Meydan N, Grinberg RD, Roisman LC. Peled N, et al. Among authors: sezer a. Lung Cancer. 2020 Oct;148:48-54. doi: 10.1016/j.lungcan.2020.07.022. Epub 2020 Jul 27. Lung Cancer. 2020. PMID: 32799090
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study.
Hizal M, Bilgin B, Paksoy N, Açıkgöz Ö, Sezer A, Gürbüz M, Ak N, Yücel Ş, Ayhan M, Erol C, Demirkıran A, Mandel NM, Shbair A, Gökmen İ, Başoğlu T, Paydaş S, Demiray AG, İriağaç Y, Şakalar T, Zeynelgil E, Tatlı AM, Bahçeci A, Güven DC, Caner B, Can A, Gülmez A, Karakaş Y, Yalçın B, Demirkazık A, Bilici A, Aydıner A, Yumuk PF, Şendur MAN. Hizal M, et al. Among authors: sezer a. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7. Epub 2021 Jul 31. J Cancer Res Clin Oncol. 2022. PMID: 34331582
193 results